Vitamin Category

By Ingredient

Search:

Special Sale!

Free Shipping on
Orders over $49

Home > Eye Vitamins >

VisiVite Premier Ocular Formula No. 2 - Based on AREDS2, 120 capsules

VisiVite Premier Ocular AREDS 2 Formula

List Price: $39.95
Our Price: $32.95
You save $7.00!

Availability:: Usually Ships in 24 to 48 Hours
Product Code: V0906

Qty:

Description

Ingredients

Extended Information

VisiVite Premier Ocular Formula No. 2 - Based on the Age Related Eye Disease 2 Study

The National Eye Institute has announced their newest Macular Degeneration Formula Study. The study is ongoing, and the final results won't be known until 2012.

VisiVite is the first and only vitamin manufacturer to offer this unique supplement based upon various aspects of the ongoing Age Related Eye Disease Study 2, and we are optimistic that the results will show not only prevention of disease progression but also improvement of vision.

In 2001, the National Eye Institute, part of the National Institutes of Health, completed the Age Related Eye Disease Study (AREDS), which showed that ingesting high levels of specific nutritional supplements decreased the risk of macular degeneration (AMD) progression. This included 25,000 IU of beta-carotene, 500 mg of Vitamin C, 400 IU of Vitamin E, 80 mg of Zinc and 2 mg of Cupric Oxide.

Unfortunately, while AREDS showed benefit by slowing the worsening of this retinal eye disease, it did not demonstrate increased vision.

Since the publication of AREDS, more recent studies, including the Lutein Antioxidant Supplement Trial, have demonstrated vision improvement. And much exciting work involving both Lutein and Zeaxanthin, molecules known as carotenoids, have shown not only vision improvement but also a healthier macular appearance with improvement in pigmentation and color.

One important issue not addressed in AREDS is that there appears to be an inflammatory component to Age-Related Macular Degeneration. Other studies suggest that Omega-3 fatty acids derived from deep sea fish may be helpful in further counteracting this eye disease and preventing blindness.

For these reasons, the National Eye Institute, in late 2006 announced the recruitment of patients into a multi-year randomized Age Related Eye Disease 2 Study. If you are interested in entering this randomized trial, we refer you to their web site, www.areds2.org.

The Age Related Eye Disease Study 2 site states:

"The Age-Related Eye Disease Study 2 (AREDS2) is a multi-center, randomized trial designed to assess the effects of oral supplementation of macular xanthophylls (lutein and zeaxanthin) and/or long-chain omega-3 fatty acids (docosahexaenoic acid) [DHA] and eicosapentaenoic acid [EPA] ) on the progression to advanced age-related macular degeneration (AMD). An additional goal of the study is to assess whether forms of the AREDS nutritional supplement with reduced zinc and/or no beta-carotene works as well as the original supplement in reducing the risk of progression to advanced AMD."

VisiVite Premier Ocular Formula Number 2 is based upon our prediction of what will be the most successful components and modifications of the Age Related Eye Disease Study 2.

We recommend VisiVite Premier Ocular Formula Number 2 for the following patients with macular degeneration:

- Progressive macular degeneration with vision loss in one or both eyes

- Presence in the retina of large drusen, pigmentation or geographic atrophy

VisiVite Premier Ocular Formula Number 2 is safe for both smokers and non-smokers (does not contain beta-carotene)